UK markets close in 3 hours 4 minutes
  • FTSE 100

    7,019.74
    +36.24 (+0.52%)
     
  • FTSE 250

    22,535.65
    +63.61 (+0.28%)
     
  • AIM

    1,251.32
    +3.19 (+0.26%)
     
  • GBP/EUR

    1.1514
    +0.0003 (+0.03%)
     
  • GBP/USD

    1.3797
    +0.0013 (+0.10%)
     
  • BTC-GBP

    44,068.55
    -1,223.35 (-2.70%)
     
  • CMC Crypto 200

    1,354.15
    -26.80 (-1.94%)
     
  • S&P 500

    4,170.42
    +45.76 (+1.11%)
     
  • DOW

    34,035.99
    +305.10 (+0.90%)
     
  • CRUDE OIL

    63.54
    +0.08 (+0.13%)
     
  • GOLD FUTURES

    1,784.20
    +17.40 (+0.98%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     
  • HANG SENG

    28,969.71
    +176.57 (+0.61%)
     
  • DAX

    15,415.46
    +160.13 (+1.05%)
     
  • CAC 40

    6,261.74
    +27.60 (+0.44%)
     

Autism - Competitive Landscape to 2026

ReportLinker
·2-min read

Summary "Autism - Competitive Landscape to 2026" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

New York, March 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Autism - Competitive Landscape to 2026" - https://www.reportlinker.com/p06035008/?utm_source=GNW


Cannabinoid receptors and Gamma-aminobutyric Acid (GABA) receptors are the major focus of drug developers.There are 44 drugs in the pipeline, five of which targets cannabinoid receptor.

Big Pharma dominates R&D in this indication, with Otsuka, Teva Pharmaceuticals, and Zelira Therapeutics leading the way. The increasing awareness and approval of late-stage pipeline molecules will drive the market growth over the next six years, but lack of curative treatment and increasing generic penetration will limit the growth.

This report provides a data-driven overview of the current and future competitive landscape in autism therapeutics.

Scope
Components of the report include -
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global autism market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global autism market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06035008/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001